

## **ADURS2020 Speakers Titles/Objectives**

### **Thursday, February 27, 2020**

**John Coster, PhD, RPh**, Director, Division of Pharmacy; Center for Medicaid & CHIP Services; Centers for Medicare & Medicaid Services OR **Cynthia Denmark, RPh**, Deputy Director, Division of Pharmacy; Center for Medicaid & CHIP Services; Centers for Medicare & Medicaid Services (CMS Invited)

**Title: CMS Update**

**No CE Hours**

### **Friday, February 28, 2020**

**Deborah Briggs, MD, FACNS**, Director, Clinical Epilepsy Service, SBSI Comprehensive Epilepsy Program, Asst. Professor, UT Dell Medical School, Austin, TX

**Title: Antiseizure Medications in the Treatment of Epilepsy**

**ACPE UAN: 0128-9999-19-049-L01-P**

**CPE: 1.0 contact hours** / Knowledge-based CPE activity

**Objectives:**

1. Identify seizure and epilepsy classifications and why this matters for treatment options
2. Describe neurologist's approach to treating epilepsy
3. Recognize medical responsiveness versus drug resistant epilepsy
4. List new treatment options to prior medications

**Jeff Barkin, MD, DFAPA** Medical Director, Cornerstone Behavioral Health; Associate Medical Director, Change Healthcare

**Title: The Assessment, Diagnosis, and Treatment of Complex Mood Disorders and Treatment Resistant Depression**

**ACPE UAN: 0128-9999-19-050-L01-P**

**CPE: 1.0 contact hours** / Knowledge-based CPE activity

**Objectives:**

1. Cite multiple underlying etiologies which present as mood disorders.
2. Examine the mood disorder spectrum and be able to differentiate across all phases of a mood disorder.
3. Examine and identify medical and non-medical factors which require optimization in individuals with mood disorders.
4. Identify rapid from non-rapid acting antidepressants and examine novel treatments including ketamine/esketamine and brexanolone.

**Amanda Ka, PharmD**, Account Consultant Pharmacist; Clinical Account Manager, OptumRx, Indiana Medicaid

**Title: Gabapentin: Off-Label Utilization and Potential Abuse**

**ACPE UAN: 0128-9999-19-051-L01-P**

**CPE: 0.5 contact hours** / Knowledge-based CPE activity

**Objectives:**

1. Identify the FDA-labeled and approved indications for use of gabapentin.
2. Describe the mechanism of action of gabapentin and how that may lend to its abuse.
3. Recognize the potential ways gabapentin is misused and abused.
4. List programs that can be utilized in an effort to ensure appropriate gabapentin use.

**Michael Ouellette, RPh**, Provider Services Director, Change Healthcare

**Title: State Roundtable - State Medicaid Programs (Part 1)**

**ACPE UAN: 0128-9999-19-052-L04-P**

**CPE: 1.0 contact hours** / Knowledge-based CPE activity

**Objectives:**

1. Review retroDUR methodologies, processes, and outcomes of State Medicaid DUR initiatives.
2. Identify environmental factors that contribute to successes and failures of State Medicaid programs medication management initiatives.
3. Describe proposals for DUR initiatives based upon the proposal phase, implementation phase, program delivery and outcome evaluation phase.

**Jack DeRuiter, PhD**, Professor, Auburn University Harrison School of Pharmacy

**Title:** Novel Drug Therapies

**ACPE UAN: 0128-9999-19-053-L01-P**

**CPE: 1.0 contact hours** / Knowledge-based CPE activity

**Objectives:**

1. Define the function of the genome, gene expression and genetic defects
2. Describe the different types of gene therapy
3. Describe the viral and non-viral vectors used for DNA delivery
4. Describe the currently approved gene therapies and their efficacy and safety and investigational gene therapies.
5. Identify the financial impact associated with gene therapy

**Amanda Ka, PharmD**, Account Consultant Pharmacist; Clinical Account Manager, OptumRx, Indiana Medicaid

**Title:** A Near Real-Time Fax-Based Approach to Retrospective Drug Utilization Review

**ACPE UAN: 0128-9999-19-055-L04-P**

**CPE: 0.5 contact hours** / Knowledge-based CPE activity

**Objectives:**

1. Explain the different types of retrospective drug utilization review communication methodologies.
2. Identify the potential benefits for near real-time faxed interventions.
3. Recognize the various types of interventions that can be used with the near real-time fax methodology.

**Michael Ouellette, RPh**, Provider Services Director, Change Healthcare

**Title:** Non-Fax-Based Approach to Retrospective Utilization Review

**ACPE UAN: 0128-9999-19-056-L04-P**

**CPE: 0.5 contact hours** / Knowledge-based CPE activity

**Objectives:**

1. Examine differences between non-faxed based approach of RetroDUR interventions to faxed based approach.
2. Examine potential benefits of non-faxed based interventions.
3. Review options for how non-faxed based interventions can drive clinically meaningful actions.

**Michael Ouellette, RPh**, Provider Services Director, Change Healthcare

**Title:** State Roundtable - State Medicaid Programs (Part 2)

**ACPE UAN: 0128-9999-19-057-L04-P**

**CPE: 1.0 contact hours** / Knowledge-based CPE activity

**Objectives:**

1. Review retroDUR methodologies, processes, and outcomes of State Medicaid DUR initiatives.
2. Identify environmental factors that contribute to successes and failures of State Medicaid programs medication management initiatives.
3. Describe proposals for DUR initiatives based upon the proposal phase, implementation phase, program delivery and outcome evaluation phase.

**Saturday, February 29, 2020**

**Thomas Frank, PharmD, BCPS, Frank Medical Consulting**

**Title:** Therapeutic Guidelines: Background, Use and Abuse

**ACPE UAN: 0128-9999-19-058-L01-P**

**CPE: 1.0 contact hours** / Knowledge-based CPE activity

**Objectives:**

1. Explain how therapeutic guidelines are developed and implemented
2. Discuss controversies related to improper development and application of therapeutic guidelines
3. Define strengths and limitations of the guidelines discussed (chronic pain, hypertension, lipids, diabetes)

**Jordan Brazeal, PharmD, Clinical Account Manager, Health Information Designs, LLC**

**Title:** New Drug Review 2019

**ACPE UAN: 0128-9999-19-059-L01-P**

**CPE: 1.0 contact hours** / Knowledge-based CPE activity

**Objectives:**

1. List indications, pharmacology, adverse effects and dosing of select new products.
2. Examine the clinical efficacy and applicability of these products.
3. Identify possible prior authorization pathways for these products.
4. Describe the economic implications of these products on state Medicaid programs.

**Maria M. Lowe, PharmD, BCPS, Director of Pharmaceutical Intelligence, Institute for Clinical and Economic Review**

**Title:** Pipeline Preview 2020

**ACPE UAN: 0128-9999-19-060-L01-P**

**CPE: 1.5 contact hours** / Knowledge-based CPE activity

**Objectives:**

1. Describe recent trends in the FDA approval process
2. Describe agents in the late-stage pipeline across key therapeutic areas
3. Identify generic equivalents for commonly used brand-name products that will be introduced to the market over the next two years

**Andy Vasquez, Deputy Associate Commissioner for Quality & Program Improvement, Texas Health & Human Services Commission**

**Title:** Using the CMS Medicaid Scorecard to Improve Recipient Health

**ACPE UAN: 0128-9999-19-061-L04-P**

**CPE: 1.0 contact hours** / Knowledge-based CPE activity

**Objectives:**

1. Explain the intent and development of the CMS Medicaid Scorecard and how to access it.
2. Review CMS Adult & Child Core Measures and the CMS Medicaid Scorecard measures.
3. List the CMS Scorecard measures related to improving health versus measures of state and federal administrative accountability.
4. Describe future plans for the CMS Scorecard and future mandatory reporting requirements for state Medicaid programs.

**Michael Ouellette, RPh, Provider Services Director, Change Healthcare**

**Title:** State Roundtable - State Medicaid Programs (Part 3)

**ACPE UAN: 0128-9999-19-062-L04-P**

**CPE: 1.0 contact hours** / Knowledge-based CPE activity

**Objectives:**

1. Review retroDUR methodologies, processes, and outcomes of State Medicaid DUR initiatives.
2. Identify environmental factors that contribute to successes and failures of State Medicaid programs medication management initiatives.
3. Describe proposals for DUR initiatives based upon the proposal phase, implementation phase, program delivery and outcome evaluation phase.



The **2020 ADURS Symposium** is designed for pharmacists specializing in medication utilization within State Medicaid programs and is sponsored by the American Drug Utilization Review Society (ADURS) and the Nebraska Council for Continuing Pharmacy Education (NCCPE). NCCPE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Credit for courses must be earned by the participant. Participants will earn **up to 12.0 contact hours** of continuing pharmacy education (CPE) credits for attendance of the entire symposium.

In order to earn CPE credits, the participant must complete an on-line educational evaluation form for each CPE session they attend within 15 days from the end of the symposium. The evaluation will collect birthdates (MMDD) and NABP e-Profile ID numbers (to receive CPE credits, the attendee must have an NABP e-Profile ID number). For more information about NABP e-Profile IDs, please see <http://www.nabp.net/programs/cpe-monitor/cpe-monitor-service/>. ACPE CPE numbers and speaker objectives can be found in the program schedule. **CPE credits will be sent to your NABP e-Profile within 45 days of the program date.** For questions about CPE credits, please email Lorilyn Joyce at [ljoyce.adurs@gmail.com](mailto:ljoyce.adurs@gmail.com).